[Form 4] OptimizeRx Corporation Insider Trading Activity

Rhea-AI Filing Summary

OptimizeRx Chief Commercial Officer Theresa Greco reported awards on Form 4 consisting of 15,625 restricted stock units and a stock option for 35,156 shares granted on 08/21/2025. The restricted stock units are a contingent right to receive common stock and will vest in three equal annual installments beginning on August 21, 2026. The stock option has an exercise price of $16.14, vests in three equal annual installments beginning August 21, 2026, is exercisable from 08/21/2026, and expires on 08/21/2030. Following the grant, Ms. Greco beneficially owns 75,981 shares of common stock and 35,156 option shares exercisable.

Positive

• 15,625 restricted stock units granted on 08/21/2025
• 35,156 stock option shares granted with a $16.14 exercise price
• Clear vesting schedule: both awards vest in three equal annual installments beginning 08/21/2026

Negative

• None.

Insights

Corporate Compensation Analyst

TL;DR: Insider received equity awards (RSUs and options) with multi-year vesting, a routine retention/compensation action for an executive.

The Form 4 documents grants made to the Chief Commercial Officer on 08/21/2025: 15,625 restricted stock units and an option for 35,156 shares at a $16.14 exercise price. Both awards vest in three equal annual installments beginning on 08/21/2026. Such awards are customary for aligning executive compensation with long-term shareholder value and retention, though the filing does not disclose grant rationale or total outstanding dilution. Impact on existing shareholders depends on future exercises and actual share settlement of RSUs.

Securities Compliance Specialist

TL;DR: Form 4 correctly reports the insider grant and vesting details; no regulatory issues disclosed in the filing.

The filing furnishes the required Section 16 disclosure: transaction date, security types, amounts, price, and post-transaction beneficial ownership. It notes vesting schedules for both RSUs and options and includes the filer’s signature by power of attorney. The document contains the standard reservation that the filer does not necessarily admit beneficial ownership for Section 16 purposes. There are no amendments or corrective disclosures in this form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Greco Theresa

(Last) (First) (Middle)

C/O OPTIMIZERX CORPORATION

260 CHARLES STREET, SUITE 302

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OptimizeRx Corp [ OPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		A	V	15,625	A	$0	75,981(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$16.14	08/21/2025		A		35,156		08/21/2026(2)	08/21/2030	Common Stock	35,156	$0	35,156	D

Explanation of Responses:

1. Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on August 21, 2026, which is the first anniversary of the grant date.

2. The stock option vests in three equal annual installments beginning August 21, 2026, the first anniversary of the grant date.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.

	/s/ Marion Odence-Ford, by Power of Attorney	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did OptimizeRx (OPRX) insider Theresa Greco receive on 08/21/2025?

Ms. Greco was granted 15,625 restricted stock units and a stock option for 35,156 shares on 08/21/2025.

When do the RSUs and options granted to Theresa Greco vest?

Both the restricted stock units and the stock option vest in three equal annual installments beginning August 21, 2026.

What is the exercise price and expiration of the option granted to Theresa Greco?

The option has an exercise price of $16.14, becomes exercisable starting 08/21/2026, and expires on 08/21/2030.

How many shares does Theresa Greco beneficially own after the reported transaction?

Following the transaction, she beneficially owned 75,981 shares of common stock plus 35,156 option shares exercisable.

Was this Form 4 filed jointly or by a single reporting person?

The Form 4 was filed by one reporting person (indicated as a single reporting person).